NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Novartis Pharmaceuticals
Conditions: Prostatic Cancer, Castration-Resistant
Interventions: JSB462, AAA617
Countries: United States, Australia, Austria, Canada, China, Czechia, France, Germany
This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated.
Sex: MALE
Age: 18 Years to —
Healthy volunteers: No
Study type: INTERVENTIONAL
Key Inclusion Criteria: * Adult male participants with histologically and/or cytologically confirmed adenocarcinoma of the prostate. Participants with mixed histology (neuroendocrine) are not eligible. * An Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) grade ≤2. * At least 1 bone or visceral metastatic lesion present on baseline CT, MRI, or bone scan imaging obtained ≤28 days prior to initiation of study treatment. * Participants must be \[68Ga\]Ga-PSMA-11 PET/CT scan positive and eligible as determined by the sponsor's central reader. * Participant must have prior exposure to at least one second generation ARPI in the metastatic/advanced setting. * Previous treatment with a maximum of 2 taxane regimens is allowed. * Participants eligible for PARPi and/or immune checkpoint inhibitor (per local testing and according to investigator's judgement) are eligible to participate if they have previous exposure to this(these) therapy(ies). Key Exclusion Criteria: * Prior treatment with any RLT (approved or investigational) is not allowed * Prior treatment with a protein degrader compound that targets AR is not allowed Other protocol-defined inclusion/exclusion criteria may apply.
- Duarte, California, United States
- Santa Monica, California, United States
- Denver, Colorado, United States
- New Haven, Connecticut, United States
- Indianapolis, Indiana, United States
- Boston, Massachusetts, United States
- Omaha, Nebraska, United States
- New York, New York, United States
- Pittsburgh, Pennsylvania, United States
- San Antonio, Texas, United States
- Darlinghurst, New South Wales, Australia
- Adelaide, South Australia, Australia
- Melbourne, Victoria, Australia
- Innsbruck, Tyrol, Austria
- Linz, Austria
- Vienna, Austria
- Burnaby, British Columbia, Canada
- Montreal, Quebec, Canada
- Beijing, China
- Beijing, China
- Olomouc, Czechia
- Prague, Czechia
- Brest, France
- Marseille, France
- Tours, France
- Essen, Germany
- Rostock, Germany
- Afula, Israel
- Beersheba, Israel
- Haifa, Israel
- + 15 more on CT.gov